HF Advisory Group LLC Raises Stock Position in Pfizer Inc. (NYSE:PFE)

HF Advisory Group LLC grew its position in shares of Pfizer Inc. (NYSE:PFE) by 3.3% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 91,402 shares of the biopharmaceutical company’s stock after acquiring an additional 2,916 shares during the quarter. Pfizer makes up 1.1% of HF Advisory Group LLC’s holdings, making the stock its 27th largest holding. HF Advisory Group LLC’s holdings in Pfizer were worth $2,425,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Aaron Wealth Advisors LLC boosted its holdings in shares of Pfizer by 18.5% in the fourth quarter. Aaron Wealth Advisors LLC now owns 19,645 shares of the biopharmaceutical company’s stock worth $521,000 after buying an additional 3,069 shares during the last quarter. Monarch Capital Management Inc. raised its position in Pfizer by 7.6% in the fourth quarter. Monarch Capital Management Inc. now owns 115,382 shares of the biopharmaceutical company’s stock worth $3,061,000 after acquiring an additional 8,152 shares during the period. Nexus Investment Management ULC boosted its stake in shares of Pfizer by 1.7% during the 4th quarter. Nexus Investment Management ULC now owns 818,287 shares of the biopharmaceutical company’s stock worth $21,709,000 after acquiring an additional 13,475 shares during the last quarter. Krilogy Financial LLC grew its position in shares of Pfizer by 69.1% during the 4th quarter. Krilogy Financial LLC now owns 46,434 shares of the biopharmaceutical company’s stock valued at $1,232,000 after acquiring an additional 18,975 shares during the period. Finally, Ameritas Advisory Services LLC increased its stake in shares of Pfizer by 3.6% in the 4th quarter. Ameritas Advisory Services LLC now owns 75,983 shares of the biopharmaceutical company’s stock worth $2,016,000 after purchasing an additional 2,633 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Trading Down 0.7 %

PFE stock opened at $26.30 on Friday. The firm has a market cap of $149.06 billion, a PE ratio of 35.55, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The firm has a fifty day moving average price of $26.08 and a 200 day moving average price of $27.99. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. During the same period in the prior year, the company earned ($0.17) EPS. The business’s revenue was up 31.2% compared to the same quarter last year. Sell-side analysts anticipate that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a yield of 6.54%. Pfizer’s dividend payout ratio (DPR) is currently 232.43%.

Insiders Place Their Bets

In other news, Director Scott Gottlieb purchased 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The shares were bought at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the acquisition, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 11.11 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. Bank of America reiterated a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. Wolfe Research started coverage on shares of Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 target price on the stock. Truist Financial reduced their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Finally, Sanford C. Bernstein assumed coverage on shares of Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price for the company. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.